Exploring Sex-Based Neuropsychological Outcomes in Pediatric Brain Cancer Survivors: A Pilot Study

Overview

Journal Diseases

Date 2024 Nov 26

PMID 39589963

Authors

Chiara Colliva

Veronica Rivi

Pierfrancesco Sarti

Isabel Cobelli

Johanna M C Blom

Affiliations

Soon will be listed here.

Abstract

Background: The increasing survival rates among pediatric cancer patients underscore the critical need to understand the long-term psychosocial impacts of cancer treatments, such as cisplatin and carboplatin. While these treatments are lifesaving, they may pose risks to neurodevelopmental processes. Despite the substantial body of research highlighting cognitive impairments associated with cancer treatments, there remains a gap in understanding how these effects differ by sex. As sex differences could inform tailored interventions and support mechanisms for affected individuals, this pilot study aimed to examine the sex differences in neuropsychological outcomes in patients treated for brain cancer with cisplatin and/or carboplatin.

Methods: Our study employed rigorous/structured neuropsychological assessments to evaluate executive functions in pediatric cancer survivors treated with cisplatin and/or carboplatin. We utilized the BRIEF and TOL tests to assess the key domains of executive function, including inhibitory control, cognitive flexibility, and problem-solving abilities. Additionally, psychosocial factors were evaluated using the Resiliency Scale to measure resilience and the PAT test to assess family psychosocial risk.

Results: In our cohort of 17 patients, significant sex differences emerged, where males outperformed females in areas such as inhibitory control, impulse regulation, and strategic planning.

Conclusions: These findings highlight the complexity of cognitive outcomes in pediatric cancer survivors. Understanding sex-specific differences is essential for developing tailored interventions that optimize cognitive and psychosocial outcomes. Future research should focus on larger cohorts and longitudinal studies to validate these findings and guide targeted interventions to improve survivorship outcomes.

References

Hudson M, Ness K, Gurney J, Mulrooney D, Chemaitilly W, Krull K . Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309(22):2371-2381. PMC: 3771083. DOI: 10.1001/jama.2013.6296. View

Orszaghova Z, Mego M, Chovanec M . Long-Term Cognitive Dysfunction in Cancer Survivors. Front Mol Biosci. 2021; 8:770413. PMC: 8713760. DOI: 10.3389/fmolb.2021.770413. View

Blom J, Barisone E, Bertolotti M, Caprino D, Cellini M, Clerici C . The Use of Psychotropic Medication in Pediatric Oncology for Acute Psychological and Psychiatric Problems: Balancing Risks and Benefits. Children (Basel). 2022; 9(12). PMC: 9777172. DOI: 10.3390/children9121878. View

Armstrong G, Liu Q, Yasui Y, Huang S, Ness K, Leisenring W . Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009; 101(13):946-58. PMC: 2704230. DOI: 10.1093/jnci/djp148. View

Steliarova-Foucher E, Colombet M, Ries L, Moreno F, Dolya A, Bray F . International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017; 18(6):719-731. PMC: 5461370. DOI: 10.1016/S1470-2045(17)30186-9. View

Ongnok B, Chattipakorn N, Chattipakorn S . Doxorubicin and cisplatin induced cognitive impairment: The possible mechanisms and interventions. Exp Neurol. 2019; 324:113118. DOI: 10.1016/j.expneurol.2019.113118. View

Soon W, Goacher E, Solanki S, Hayes J, Kapetanstrataki M, Picton S . The role of sex genotype in paediatric CNS tumour incidence and survival. Childs Nerv Syst. 2021; 37(7):2177-2186. PMC: 8263540. DOI: 10.1007/s00381-021-05165-0. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Willard V, Gordon M, Means B, Brennan R, Conklin H, Merchant T . Social-Emotional Functioning in Preschool-Aged Children With Cancer: Comparisons Between Children With Brain and Non-CNS Solid Tumors. J Pediatr Psychol. 2021; 46(7):790-800. DOI: 10.1093/jpepsy/jsab018. View

10.

Libes J, Hol J, de Aguirre Neto J, Vallance K, van Tinteren H, Benedetti D . Pediatric renal tumor epidemiology: Global perspectives, progress, and challenges. Pediatr Blood Cancer. 2023; 70 Suppl 2:e30343. DOI: 10.1002/pbc.30343. View

11.

Gurney J, Krull K, Kadan-Lottick N, Nicholson H, Nathan P, Zebrack B . Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27(14):2390-5. PMC: 2677924. DOI: 10.1200/JCO.2008.21.1458. View

12.

Kazak A, Schneider S, DiDonato S, Pai A . Family psychosocial risk screening guided by the Pediatric Psychosocial Preventative Health Model (PPPHM) using the Psychosocial Assessment Tool (PAT). Acta Oncol. 2015; 54(5):574-80. DOI: 10.3109/0284186X.2014.995774. View

13.

Kaplan S, Limbocker R, Gehringer R, Divis J, Osterhaus G, Newby M . Impaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with Carboplatin. ACS Chem Neurosci. 2016; 7(6):689-99. PMC: 4911621. DOI: 10.1021/acschemneuro.5b00029. View

14.

Dasari S, Njiki S, Mbemi A, Yedjou C, Tchounwou P . Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy. Int J Mol Sci. 2022; 23(3). PMC: 8835907. DOI: 10.3390/ijms23031532. View

15.

Spencer M, Cutting L . Relations Among Executive Function, Decoding, and Reading Comprehension: An Investigation of Sex Differences. Discourse Process. 2021; 58(1):42-59. PMC: 7954233. DOI: 10.1080/0163853X.2020.1734416. View

16.

Ranasinghe R, Mathai M, Zulli A . Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon. 2022; 8(9):e10608. PMC: 9489975. DOI: 10.1016/j.heliyon.2022.e10608. View

17.

Smith M, Seibel N, Altekruse S, Ries L, Melbert D, OLeary M . Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010; 28(15):2625-34. PMC: 2881732. DOI: 10.1200/JCO.2009.27.0421. View

18.

Fisher R, Rausch J, Ferrante A, Prussien K, Olshefski R, Vannatta K . Trajectories of health behaviors across early childhood cancer survivorship. Psychooncology. 2018; 28(1):68-75. PMC: 6545194. DOI: 10.1002/pon.4911. View

19.

Mileva-Seitz V, Ghassabian A, Bakermans-Kranenburg M, van den Brink J, Linting M, Jaddoe V . Are boys more sensitive to sensitivity? Parenting and executive function in preschoolers. J Exp Child Psychol. 2014; 130:193-208. DOI: 10.1016/j.jecp.2014.08.008. View

20.

Matheson K, Asokumar A, Anisman H . Resilience: Safety in the Aftermath of Traumatic Stressor Experiences. Front Behav Neurosci. 2021; 14:596919. PMC: 7779406. DOI: 10.3389/fnbeh.2020.596919. View